About: Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Its pipeline includes small molecule therapeutics to treat inflammation across cardiometabolic disorders, neurodegenerative diseases, and inflammatory disorders. The company's portfolio of NLRP3 inhibitors includes VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn's disease. It is also developing Tamuzimod, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor that is in a Phase 2a trial for patients with early Parkinson's disease and is in a Phase 2 trial for patients with obesity and additional risk factors for cardiovascular disease. Ventyx Biosciences, Inc. was incorporated in 2018 and is headquartered in San Diego, California. As of March 4, 2026, Ventyx Biosciences, Inc. operates as a subsidiary of Eli Lilly and Company.
Sector: Healthcare
Industry: Biotechnology
Status: deslistada — removed_from_provider. Este ativo não é mais negociado; são exibidos dados históricos.
VTYX NASDAQ Ventyx Biosciences Inc
Ventyx Biosciences Inc share price
Atividade de preço de VTYX
Último preço
Variação (24h)
USD
Volume
-
Volume (média 4 sem.)
-
Fechamento anterior
N/D
Último negócio
VTYX price performance
quote.marketSignals